Assembly Biosciences (ASMB) vs Kamada (KMDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Kamada (KMDA) has outperformed Assembly Biosciences (ASMB) over the past year, gaining 18.6% versus a loss of 3.8%. Over five years, KMDA leads with a +49.7% price change compared with -41.3% for ASMB. Assembly Biosciences is the larger company by market cap ($467.3 million vs $455.3 million), about 1.0 times the size.
On valuation, Assembly Biosciences trades at a lower trailing P/E (21.3x vs 21.3x for Kamada). Kamada pays a dividend yielding 3.17%, while Assembly Biosciences does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ASMB | KMDA |
|---|---|---|
| Share price | $22.95 | $7.89 |
| Market cap | $467.28M | $455.33M |
| 1-day change | +3.47% | -2.71% |
| YTD return | -32.52% | +11.76% |
| 1-year return | -3.81% | +18.65% |
| 5-year return | -41.33% | +49.72% |
| P/E ratio (TTM) | 21.25 | 21.32 |
| Forward P/E | — | 13.68 |
| EPS (TTM) | $1.08 | $0.37 |
| Dividend yield | 0.00% | 3.17% |
| Annual dividend | $0.00 | $0.25 |
| 52-week high | $39.71 | $9.35 |
| 52-week low | $21.80 | $6.55 |
| Distance from 52-week high | -42.21% | -15.61% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +126.58% | +71.10% |
| Average volume | 277.22K | 118.76K |
| Shares outstanding | 20.36M | 57.71M |
| Employees | 73 | 462 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KMDA has outperformed ASMB by 22.5 percentage points over the past year.
- Kamada offers a meaningfully higher dividend yield (3.17% vs 0.00%).
About Assembly Biosciences
ASMB stock →Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection.
Healthcare · Biotechnology · 73 employees
About Kamada
KMDA stock →Kamada Ltd. manufactures and sells plasma-derived protein therapeutics.
Healthcare · Drug Manufacturers - Specialty & Generic · 462 employees
ASMB vs KMDA FAQ
Which is bigger, Assembly Biosciences or Kamada?
Assembly Biosciences (ASMB) is larger, with a market capitalization of $467.28M compared with $455.33M for Kamada (KMDA).
Which stock has performed better over the past year, ASMB or KMDA?
KMDA returned +18.65% over the past 12 months, compared with -3.81% for ASMB (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ASMB or KMDA?
ASMB has the lower trailing P/E at 21.3, versus 21.3 for KMDA. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Assembly Biosciences or Kamada?
Kamada pays a dividend yielding 3.17%, while Assembly Biosciences does not currently pay a regular dividend.
Are Assembly Biosciences and Kamada in the same industry?
Both are in the Healthcare sector, but in different industries: Biotechnology for Assembly Biosciences and Drug Manufacturers - Specialty & Generic for Kamada.